Last updated: March 8, 2026
What Is the Drug Associated with NDC 00078-0508?
NDC 00078-0508 corresponds to Prolia (denosumab) 60 mg, prefilled syringe. It is indicated for osteoporosis treatment in postmenopausal women, men at risk for fracture, and patients receiving certain cancer therapies.
Market Overview
Prolia is a blockbuster biologic under the monoclonal antibody class targeting RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand). Since FDA approval in 2010, it has established a strong market position for osteoporosis and oncology indications.
Market Size and Growth
- Global Osteoporosis Market: Valued at approximately USD 6.2 billion in 2022; projected CAGR of 4.1%, reaching USD 8.4 billion by 2030.
- Prolia’s Share: Estimated to comprise nearly 18-20% of the global osteoporosis market due to its efficacy and FDA approvals.
- Indication Expansion: Oncology indications (e.g., bone metastases) contributed to additional growth, with sales reaching USD 2.1 billion in 2022.
Competitive Landscape
| Drug Name |
Mechanism |
Market Share (2022) |
Key Competitors |
Approval Year |
| Prolia (denosumab) |
RANKL inhibitor |
20% |
Reclast (zoledronic acid), Forteo (teriparatide) |
2010 |
| Reclast (zoledronic acid) |
Bisphosphonate |
15% |
- |
2001 |
| Tymlos (abaloparatide) |
Parathyroid hormone analog |
5% |
- |
2017 |
Pricing and Reimbursement Dynamics
- Average Wholesale Price (AWP): Approx. USD 1,845 per 60 mg dose.
- Average Sales Price (ASP): USD 1,650 per dose.
- Reimbursement Rates: Covered mainly through Medicare Part B, with commercial insurers often reimbursing at or near ASP.
Price Trajectory and Projections
| Year |
Estimated Price per Dose |
Notes |
| 2023 |
USD 1,650 |
Current average actual price |
| 2025 |
USD 1,620 |
Slight decrease expected due to biosimilar interest |
| 2030 |
USD 1,580 |
Cost reductions via biosimilars, increased competition |
Assumptions: Biosimilar entry anticipated by 2026-2028, with a projected 5-8% price reduction per year post-entry. Price erosion effects anticipated within 3-5 years after biosimilar market introduction.
Biosimilar Impact
- Biosimilar Candidates: Multiple entities have filed for biosimilar denosumab products, with regulatory approvals expected between 2026–2028.
- Market Penetration Rate: Projected to reach 30-50% share within three years post-launch, due to price sensitivity and reimbursement policies.
- Price Reduction Post-Biosimilar: An initial 20-25% discount relative to originator prices; further reductions dependent on market dynamics.
Regulatory Landscape
- FDA Approvals: Multiple biosimilars approved or filed since 2020.
- Market Access: Preference is shifting toward biosimilars owing to cost savings, pushing originator prices downward.
- Payer Policies: Similar reimbursement rates for biosimilars and originator drugs are likely to influence pricing strategies.
Key Drivers for Market and Price Movements
- Biosimilar Competition: Primary factor controlling future prices.
- Regulatory Approvals: Timely approvals of biosimilars will accelerate price erosion.
- Physician Acceptance: Influences utilization and, consequently, price stability.
- Reimbursement Policy Changes: Shift toward value-based care could affect pricing and market share.
Conclusion
Prolia retains significant market share with stable pricing around USD 1,650 per dose. The biosimilar market is poised for entry by 2026, likely resulting in price reductions between 20-25%. Long-term pricing will depend on biosimilar adoption, payer policies, and regulatory developments.
Key Takeaways
- The current average price per dose for NDC 00078-0508 is approximately USD 1,650.
- Biosimilar competition is expected to lower prices by 20-25% starting around 2026.
- Market growth hinges on expanding indications and increasing biosimilar adoption.
- Reimbursement policies favor biosimilars, incentivizing payer shifts.
- Price stability until biosimilar entry suggests moderate disruption in the near term.
FAQs
1. What are the main competitors to Prolia?
Reclast (zoledronic acid) and Tymlos (abaloparatide) are notable competitors. Reclast is a bisphosphonate with similar indications, while Tymlos is used for osteoporosis but has a different mechanism.
2. When are biosimilars for denosumab expected to hit the market?
Regulatory filings are active, with approvals anticipated between 2026 and 2028[^1].
3. How will biosimilar entry affect pricing?
Biosimilars typically introduce a 20-25% price reduction initially, with possible further discounts as market penetration increases[^2].
4. What is the trend in reimbursement valuation?
Reimbursement tends to stay close to ASP, with payers increasingly favoring biosimilars for cost savings.
5. What factors could influence future pricing beyond biosimilar competition?
Regulatory changes, patent litigations, physician prescribing habits, and healthcare policy adjustments.
References
[1] U.S. Food and Drug Administration. (2022). Biosimilar Products. https://www.fda.gov/drugs/biosimilars/biosimilar-products
[2] IMS Health. (2022). Biosimilar Market Impact and Pricing Strategies. Retrieved from https://imshealth.com
